Xcopri(Cenobamat) Side Effects

Discontinuation rates due to adverse effects range from 9% (200 mg) to 21% (400 mg).

Clinical and Postmarketing Safety Profile  

Common adverse reactions (≥10% incidence) include somnolence (19–37%), dizziness (18–33%), fatigue (12–24%), diplopia (6–15%), and headache (10%). Serious reactions include DRESS, hepatic failure (postmarketing), and QT interval shortening. Laboratory abnormalities include elevated ALT (>3× ULN in 2.7% at 400 mg) and hyperkalemia (up to 10.8%). Neuropsychiatric events (e.g., psychosis, aggression) and dependence/withdrawal symptoms (insomnia, tremor) are noted postmarketing.